Search results
Goldman Sachs Gr's Options Frenzy: What You Need to Know - Goldman Sachs Gr (NYSE:GS)
Benzinga· 10 hours agoAround 60% of the company's net revenue is generated in the...Africa. Following our analysis of the options activities associated with Goldman Sachs Gr, ...
Goldman Sachs Turns Neutral on Tata Motors Amidst Marginal Downturn
Investing.com· 20 hours agoGoldman Sachs Turns Neutral on Tata Motors Amidst Marginal Downturn
Zacks Industry Outlook Highlights Morgan Stanley, The Goldman Sachs and Piper Sandler
Zacks via Yahoo Finance· 6 days agoThese factors will keep aiding investment banks like Morgan Stanley, The Goldman Sachs Group, Inc....
Supreme for Sale? VF Said to Be Shopping the Streetwear Brand
WWD via Yahoo Finance· 4 hours agoAs those charges were logged, VF’s now outgoing chief financial officer, Matthew Puckett,...
Is EverQuote (EVER) Stock Outpacing Its Finance Peers This Year?
Zacks via Yahoo Finance· 4 days agoThis group has gained an average of 12.8% so far this year, so EVER is performing better in this...
Goldman Sachs BDC, Inc. (NYSE:GSBD) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoGoldman Sachs BDC, Inc. (NYSE:GSBD) Q1 2024 Earnings Call Transcript May 8, 2024 Goldman Sachs BDC,...
Wealth Management EDGE: Duran Says PE Demands Bring National RIAs Closer to Wirehouses
WealthManagement.com· 10 hours agoDuring a conversation with WealthManagement.com Managing Editor Diana Britton at Wealth Management...
Why Goldman Bought, and Sold, United Capital | ThinkAdvisor
ThinkAdvisor· 2 days agoThe acquisition was intended to extend Goldman’s reach and capabilities in an exciting growth market, Waldron explained during a wide-ranging Q&A held during the firm’s inaugural ...
3 Market Surprises Highlighted at Goldman’s RIA Conference
Barrons.com· 1 day agoBEST PRACTICES Will we have a soft landing or hard landing? Is a productivity boom around the...
Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded to Buy at StockNews.com
ETF DAILY NEWS· 19 hours agoBarclays lifted their price target on shares of Teva Pharmaceutical Industries from $17.00 to $20.00 and gave the stock an overweight rating in a report on Thursday, May 9th. The Goldman ...